The agenda for the 20 May 2015 TC meeting is now available. The Commission will consider the following technologies:

• Sorafenib tosylate (Nexavar) - new indication
• Meningococcal Groups A, C, W135 & Y conjugate vaccine (Menveo) - new vaccine
• Meningococcal Groups A, C, W135 & Y conjugate vaccine (Nimenrix) - new vaccine
• Telavancin hydrochloride (Vibativ) - new medicine
• Alipogene tiparvovec (Glybera) - new medicine
• Eliglustat tartrate (Cerdelga) - new medicine
• Ofatumumab acetate (Arzerra) - new indication
• Pazopanib hydrochloride (Votrient) - review of SMR

For more details, go to: http://www.has-sante.fr/portail/upload/docs/application/pdf/2015-05/odj_ct_20052015_internet.pdf [French]